Bisphosphonates for Osteoporosis: Podcast with James Deardorff and Sei Lee
GeriPal
FEBRUARY 17, 2022
When we have a medication with up front harms and downstream benefits, it’s critical that we consider the time to benefit, or how long it will take an individual to benefit from a test or treatment. For individuals with a life expectancy less than the time to benefit, the up front harms outweigh the downstream benefits. . James: Yeah.
67 
Let's personalize your content